Safety of systemic anti-cancer treatment in oncology patients with non-severe COVID-19: a cohort study

BMC Cancer

Table 3 Factors potentially associated with hematological toxicity

Factor	Univariate analysis		Multivariate analysis
Factor	Odds ratio (95% CI)	P	Odds ratio (95% CI)	P
Age (≥ 65 vs < 65 years)	0.947 (0.617–1.455)	0.804
SARS-CoV-2 status (positive vs negative)	4.974 (1.897–13.048)	0.001	4.061 (1.421–11.606)	0.009
Comorbidity (absent vs present)	0.848 (0.552–1.300)	0.449
Cancer type (other vs lung)	1.260 (0.695–2.284)	0.447
Disease extent (localized vs metastatic)	1.521 (0.973–2.378)	0.066
ECOG (2–3 vs 0–1)	5.357 (1.424–20.149)	0.013	6.718 (1.517–29.745)	0.012
COVID-19 symptoms*: yes vs no	1.192 (0.661–2.151)	0.559
Treatment:
Chemotherapy vs immunotherapy	12.172 (5.950–24.900)	< 0.001	11.435 (5.519–23.692)	< 0.001
Chemotherapy + immunotherapy vs immunotherapy	11.280 (3.898–32.645)	< 0.001	10.361 (3.495–30.719)	< 0.001
Other vs immunotherapy	2.452 (0.987–6.094)	0.053	2.157 (0.846–5.496)	0.107

* Fever, cough or anosmia
CI confidence interval; COVID-19: The viral pandemic coronavirus disease 2019; SARS-CoV-2: severe acute respiratory syndrome coronavirus-2, ECOG Eastern Cooperative Oncology Group; vs: versus

ISSN: 1471-2407